<DOC>
	<DOCNO>NCT02714218</DOCNO>
	<brief_summary>The purpose study evaluate two different dose combination nivolumab ipilimumab treatment melanoma .</brief_summary>
	<brief_title>A Study Two Different Dose Combinations Nivolumab Combination With Ipilimumab Subjects With Previously Untreated , Unresectable Metastatic Melanoma</brief_title>
	<detailed_description />
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<mesh_term>Nivolumab</mesh_term>
	<criteria>For information regard BristolMyers Squibb Clinical Trial participation , please visit www.BMSStudyConnect.com Subject must diagnose stage III or/and stage IV histologically confirm melanoma [ per American Joint Committee Cancer ( AJCC ) stag system ] unresectable metastatic Eastern Cooperative Oncology Group ( ECOG ) performance status 01 Subject treat systemic anticancer therapy unresectable metastatic melanoma Subjects active brain metastasis leptomeningeal metastasis Subjects ocular melanoma Subjects active , know suspected autoimmune disease Other protocol define inclusion/exclusion criterion could apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>